Stromal PD‐1/PD‐L1 Expression Predicts Outcome in Colon Cancer Patients
来源期刊：Clinical Colorectal CancerDOI：10.1016/j.clcc.2018.09.007
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2018.12.006
Bolus 5‐fluorouracil (5‐FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5‐FU or Capecitabine
来源期刊：Clinical Colorectal CancerDOI：10.1016/j.clcc.2018.09.006
5‐Fluorouracil‐related Cardiotoxicity; Findings From Five Randomized Studies of 5‐Fluorouracil‐based Regimens in Metastatic Colorectal Cancer
来源期刊：Clinical Colorectal CancerDOI：10.1016/j.clcc.2018.10.006
Pattern, Stage, and Time of Recurrent Colorectal Cancer After Curative Surgery.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.01.003
Review: Pathology and Its Clinical Relevance of Mucinous Appendiceal Neoplasms and Pseudomyxoma Peritonei.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2018.11.007
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology.
来源期刊：Clinical colorectal cancerDOI：10.1016/J.CLCC.2019.02.008
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.02.004
Prognostic Effect of Tumor Sidedness in Colorectal Cancer: A SEER‐Based Analysis
来源期刊：Clinical Colorectal CancerDOI：10.1016/j.clcc.2018.10.005
Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
来源期刊：Clinical colorectal cancerDOI：10.1016/J.CLCC.2019.04.003
Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal
来源期刊：Clinical Colorectal CancerDOI：10.1016/j.clcc.2018.08.001
E‐Cadherin in Colorectal Cancer: Relation to Chemosensitivity
来源期刊：Clinical Colorectal CancerDOI：10.1016/j.clcc.2018.10.003
The Role of the Gut Microbiome in Colorectal Cancer: Where Are We? Where Are We Going?
来源期刊：Clinical colorectal cancerDOI：10.1016/J.CLCC.2019.07.006
Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.02.005
Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987‐2016
来源期刊：Clinical Colorectal CancerDOI：10.1016/j.clcc.2018.10.001
Trends in Colorectal Cancer Incidence and Survival in Iowa SEER Data: The Timing of It All.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2018.12.001
Effects of Adjuvant Chemotherapy on Cognitive Function of Patients With Early‐stage Colorectal Cancer
来源期刊：Clinical Colorectal CancerDOI：10.1016/j.clcc.2018.09.002
Disqualification of Neoadjuvant Rectal Score Based on Data of 6596 Patients From the Netherlands Cancer Registry.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.01.001
Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2018.12.004
Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
来源期刊：Clinical colorectal cancerDOI：10.1016/J.CLCC.2019.07.007
A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer.
来源期刊：Clinical colorectal cancerDOI：10.1016/J.CLCC.2019.06.004
KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.05.004
Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.08.003
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.08.004
Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High‐Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI‐PRODIGE Trial
来源期刊：Clinical Colorectal CancerDOI：10.1016/j.clcc.2018.09.011
Diagnostic Nodes of Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Among Colorectal Cancer Patients: A Swiss National Multicenter Survey.
来源期刊：Clinical colorectal cancerDOI：10.1016/J.CLCC.2019.06.002
ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK.
来源期刊：Clinical colorectal cancerDOI：10.1016/J.CLCC.2019.07.003
FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer
来源期刊：Clinical Colorectal CancerDOI：10.1016/j.clcc.2018.09.005
What is the Optimal Preoperative Imaging Modality for Assessing Peritoneal Cancer Index? An Analysis From the United States HIPEC Collaborative.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.12.002
Safety and Oncological Outcomes of Bevacizumab Therapy in Patients With Advanced Colorectal Cancer and Self-expandable Metal Stents.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.05.009
Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei.
来源期刊：Clinical colorectal cancerDOI：10.1016/J.CLCC.2019.03.002
Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.07.001
Prognostic Effect of Adenosine‐related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab‐based Chemotherapy
来源期刊：Clinical Colorectal CancerDOI：10.1016/j.clcc.2018.09.003
Overuse and Limited Benefit of Chemotherapy for Stage II Colon Cancer in Young Patients.
来源期刊：Clinical colorectal cancerDOI：10.1016/J.CLCC.2019.04.002
Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma.
来源期刊：Clinical colorectal cancerDOI：10.1016/J.CLCC.2019.05.002
Network Mapping of Molecular Biomarkers Influencing Radiation Response in Rectal Cancer.
来源期刊：Clinical colorectal cancerDOI：10.1016/J.CLCC.2019.01.004
Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
来源期刊：Clinical colorectal cancerDOI：10.1016/J.CLCC.2019.04.006
Survival Outcomes After Surgical Management of the Primary Tumor With and Without Radiotherapy for Metastatic Rectal Adenocarcinoma: A National Cancer Database (NCDB) Analysis.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2018.12.005
Impact of Single-organ Metastasis to the Liver or Lung and Genetic Mutation Status on Prognosis in Stage IV Colorectal Cancer.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.12.001
ACTH‐Secreting Neuroendocrine Carcinoma of the Cecum: Case Report and Review of the Literature
来源期刊：Clinical Colorectal CancerDOI：10.1016/j.clcc.2018.07.013
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines‐Pretreated or High‐Risk Cardiac Patients With GI Malignancies: Large Single‐Center Experience
来源期刊：Clinical Colorectal CancerDOI：10.1016/j.clcc.2018.09.010
Effect of Responsiveness of Lymph Nodes to Preoperative Chemoradiotherapy in Patients With Rectal Cancer on Prognosis After Radical Resection.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.03.001
Colon Cancer Tumor Location Defined by Gene Expression May Disagree With Anatomic Tumor Location.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.02.002
Type and Consequences of Short-Term Complications in Colon Cancer Surgery, Focusing on the Oldest Old.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.11.003
Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
来源期刊：Clinical colorectal cancerDOI：10.1016/J.CLCC.2019.06.006
Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.06.001
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
来源期刊：Clinical colorectal cancerDOI：10.1016/J.CLCC.2019.07.009
Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.08.005
Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer.
来源期刊：Clinical colorectal cancerDOI：10.1016/j.clcc.2019.10.006
Pathologic Staging Inconsistency Between ypT4N0 (stage II) and ypT1‐2N1 (stage III) After Preoperative Chemoradiotherapy and Total Mesorectal Excision in Rectal Cancer: A Multi‐Institutional Study
来源期刊：Clinical Colorectal CancerDOI：10.1016/j.clcc.2018.11.003
投稿咨询
加急服务
论文发表
2-4个月录用
7500+文章录用
不成功可退款
